Immune Effects
How mebendazole may support anti-tumour immune responses through its unusual ERK-related effects
Mebendazole's immune relevance is especially interesting because of its ERK / MAPK duality.
Immune overview
In tumour cells, mebendazole appears to suppress ERK-related survival signalling. In immune cells, it may activate ERK-linked pathways in ways that support anti-tumour immune responses.
Why this matters
That means mebendazole may do two things at once:
weaken ERK-driven tumour survival
strengthen parts of the immune response against the tumour
This is one of the reasons it stands out among repurposed and integrative oncology candidates.
Practical interpretation
The immune discussion remains emerging, but it strengthens the case for mebendazole as a multi-pronged adjunct rather than a simple anti-mitotic drug.
Key References
Mebendazole as a Candidate for Drug Repurposing in Oncology
https://pmc.ncbi.nlm.nih.gov/articles/PMC6769799/
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.